CÔNG TY CỔ PHẦN DƯỢC PHẨM ĐẠT VI PHÚ (DAVIPHARM)

• Quy mô

  100-499 nhân viên

• Lĩnh vực

  Dược phẩm

Domestic manufacturer with European standards We are one of the leading domestic manufacturers of high-quality medicinal products. Established in 2004, certified in 2007 with WHO-GMP, in 2014 Davipharm reached first 100 registered products and started exporting its medicines to the Philippines and Cambodia. In 2017 Adamed Pharma S.A. acquired the controlling stake in Davipharm to upgrade the production standards, execute technology transfers, and develop export. In 2021 we opened the first certified HP Zone in Vietnam. Later that same year Davipharm had been certified with its first EU-GMP for the manufacturing operations (production and packing) of non-sterile products in capsules, hard shells and tablets. Since 2022 we have been focusing on the technology transfers. In 2023, Adamed acquired the remaining shares in Davipharm, becoming its sole shareholder. This acquisition infused Davipharm with a new vision centered on producing high-quality products adhering to EU-GMP standards and allowing the international expansion. The integration with the Adamed Group plays a pivotal role in the company transformation. The harmonization of operational processes, sharing resources, learning from the best practices and following the corporate values, supports our efforts on the way to business excellence. Our strategic goals include reaching a top position in the domestic market and becoming number 1 pharmaceutical exporting company in Vietnam, focusing on R&D excellence and new products launches, contract manufacturing, and close cooperation with academia to support products development and expand talent pools. Implementing ESG standards will ensure Davipharm’s position as a reliable and desired partner in the global supply chain. Emblematic of the foreign investment When in 2017 Adamed Pharma S.A. acquired 70% of shares in Davipharm, becoming the biggest direct Polish investor in Vietnam, it set very ambitious goals. With US$60 million investment to date, out of which over US$10 million has been spent on the upgrade of manufacturing processes and products quality, the company committed to contribute to the local economy not only by paying taxes and creating jobs, but also by providing high-quality medicines at affordable prices to local patients, thus supporting the Ministry of Health of Vietnam to optimize the spending on drugs. HP Zone and EU-GMP Davipharm’s High Potency Drugs (HP) Zone for production of cytotoxic/cytostatic oral solids was the first certified by DAV area in Vietnam for manufacturing, among other, oncology drugs in hard shell capsules, tablets, and coated tablets. Davipharm’s portfolio includes 28 HP drugs, including medicines to treat breast cancer, leukemia, pancreas, colorectal, stomach, cervix, prostate and lung cancer and glioblastoma. In 2024, Davipharm got certified with EU-GMP for its HP Zone. This is the first HP Zone EU-GMP certification in Vietnam and in the region. This milestone highlights Davipharm’s pioneering role in the Vietnamese pharmaceutical industry and its unwavering commitment to maintaining the highest production standards. Additionally, the company was re-certified with EU-GMP for non-sterile products such as hard capsules and tablets.